{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Dewdney.jpg|frameless|upright=0.3|center]]
|<big>[[User:Summerdewdney|Summer B. Dewdney, MD]]<br>Chicago, IL</big>
|-
|}
''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Ovarian_cancer_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''.
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[http://www.asco.org/ ASCO]==
*'''2016:''' Wright et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512594/ Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline]

==[http://www.esmo.org/ ESMO]==
*'''2016:''' Ledermann et al. [https://www.esmo.org/Guidelines/Gynaecological-Cancers/Newly-Diagnosed-and-Relapsed-Epithelial-Ovarian-Carcinoma/eUpdate-Treatment-Recommendations eUpdate – Ovarian Cancer Treatment Recommendations]
===Older===
*'''2013:''' Ledermann et al. [http://annonc.oxfordjournals.org/content/24/suppl_6/vi24.full.pdf+html Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/24078660 PubMed]
*'''2012:''' Colombo et al. [http://annonc.oxfordjournals.org/content/23/suppl_7/vii20.full.pdf+html Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/22997450 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf NCCN Guidelines - Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer]

=Adjuvant therapy for early stage disease=
==Carboplatin & Paclitaxel {{#subobject:cdf21c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:841d9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(06)00478-1/fulltext Bell et al. 2006 (GOG 157)]
|style="background-color:#1a9851"|Phase III (C)
|CP x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Ovarian_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 7.5 IV over 30 minutes once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for 3 cycles'''
===References===
# '''GOG 157:''' Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM; Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Sep;102(3):432-9. Epub 2006 Jul 24. [https://www.gynecologiconcology-online.net/article/S0090-8258(06)00478-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16860852 PubMed]
# '''GOG-0175:''' Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011 Jul;122(1):89-94. Epub 2011 May 6. [https://www.gynecologiconcology-online.net/article/S0090-8258(11)00188-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110746/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21529904 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199004123221501 Young et al. 1990]
|style="background-color:#1a9851"|Phase III (C)
|Melphalan
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/jnci/article/95/2/113/2912344 Trimbos et al. 2003 (ACTION)]
|style="background-color:#1a9851"|Phase III (C)
|Platinum-based chemotherapy
| style="background-color:#fc8d59" |Seems to have inferior RFS
|-
|[https://academic.oup.com/jnci/article/95/2/125/2912345 Colombo et al. 2003 (ICON1)]
|style="background-color:#1a9851"|Phase III (C)
|Platinum-based chemotherapy
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110746/ Mannel et al. 2011 (GOG-0175)]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel maint.
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further treatment.''
====Preceding treatment====
*Young et al. 1990; ACTION; ICON1: [[Surgery#Ovarian_cancer_surgery|Surgery]]
*GOG-0175: [[Surgery#Ovarian_cancer_surgery|Surgery]], then [[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]] x 3

===References===
# Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990 Apr 12;322(15):1021-7. [https://www.nejm.org/doi/full/10.1056/NEJM199004123221501 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2181310 PubMed]
# '''ACTION:''' Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S; EORTC-ACTION collaborators. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003 Jan 15;95(2):113-25. [https://academic.oup.com/jnci/article/95/2/113/2912344 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12529344 PubMed]
## '''Pooled analysis:''' Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. [https://academic.oup.com/jnci/article/95/2/105/2964945 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12529343 PubMed]
# '''ICON1:''' Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, Bonazzi C; International Collaborative Ovarian Neoplasm (ICON) collaborators. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003 Jan 15;95(2):125-32. [https://academic.oup.com/jnci/article/95/2/125/2912345 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12529345 PubMed]
## '''Pooled analysis:''' Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. [https://academic.oup.com/jnci/article/95/2/105/2964945 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12529343 PubMed]
# '''GOG-0175:''' Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011 Jul;122(1):89-94. Epub 2011 May 6. [https://www.gynecologiconcology-online.net/article/S0090-8258(11)00188-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110746/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21529904 PubMed]

=Neoadjuvant chemotherapy for advanced stage disease=
==Carboplatin & Paclitaxel {{#subobject:ab0654|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, AUC 5/175 x 3 {{#subobject:68d2cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62223-6/fulltext Kehoe et al. 2015 (CHORUS)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Adjuvant Carboplatin & Paclitaxel]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Interval_debulking_surgery|Interval debulking surgery]], then [[#Carboplatin_.26_Paclitaxel_3|adjuvant Carboplatin & Paclitaxel]] x 3

===Variant #2, AUC 5/175 x 6 {{#subobject:d2168a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.ejcancer.com/article/S0959-8049(16)00072-1/fulltext Fagotti et al. 2016 (SCORPION)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Adjuvant Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#1a9850" |Superior QoL
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Surgery#Interval_debulking_surgery|Interval debulking surgery]]

===Variant #3, AUC 6/175 x 3 {{#subobject:f05e45|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0908806 Vergote et al. 2010 (EORTC 55971)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Adjuvant Carboplatin & Paclitaxel]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62223-6/fulltext Kehoe et al. 2015 (CHORUS)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Adjuvant Carboplatin & Paclitaxel]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Interval_debulking_surgery|Interval debulking surgery]], then [[#Carboplatin_.26_Paclitaxel_3|adjuvant Carboplatin & Paclitaxel]] x 3
===References===
# '''EORTC 55971:''' Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. [https://www.nejm.org/doi/full/10.1056/NEJMoa0908806 link to original article] '''contains protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/20818904 PubMed]
# '''CHORUS:''' Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249-57. Epub 2015 May 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62223-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26002111/ PubMed]
# '''SCORPION:''' Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016 May;59:22-33. Epub 2016 Mar 19. [https://www.ejcancer.com/article/S0959-8049(16)00072-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26998845 PubMed]

=First-line chemotherapy for advanced stage disease=
''Note: in a majority of these regimens, chemotherapy was preceded by primary debulking surgery.''

==Carboplatin monotherapy {{#subobject:4f85d8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, AUC 5 {{#subobject:07553c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)04119-1/fulltext Parmar et al. 1998 (ICON2)]
|style="background-color:#1a9851"|Phase III (E)
|[[Ovarian_cancer_-_historical#CAP_.28Platinol.29|CAP]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140673602097386/fulltext Parmar et al. 2002 (ICON3)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[Ovarian_cancer_-_historical#CAP_.28Platinol.29|CAP]]<br> 2. [[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #2, AUC 6, q3wk {{#subobject:8672ea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140673602097386/fulltext Parmar et al. 2002 (ICON3)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[Ovarian_cancer_-_historical#CAP_.28Platinol.29|CAP]]<br> 2. [[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669851/ Banerjee et al. 2012 (SCOTROC 4)]
|style="background-color:#1a9851"|Phase III (C)
|Dose-escalated Carboplatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #3, AUC 6, q4wk {{#subobject:9e367c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.7.2426 Gore et al. 1998]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin AUC 12 x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1

'''28-day cycle for 6 cycles'''

===Variant #4, 400 mg/m<sup>2</sup>, q4wk {{#subobject:68b7cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-abstract/81/19/1464/952730 Mangioni et al. 1989]
|style="background-color:#1a9851"|Phase III (C)
|[[Ovarian_cancer_-_historical#Cisplatin_monotherapy|Cisplatin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2066 Taylor et al. 1994]
|style="background-color:#1a9851"|Phase III (C)
|[[Ovarian_cancer_-_historical#Cisplatin_monotherapy|Cisplatin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Of historic interest.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] 400 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 10 cycles'''

===References===
# Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, Vassena L, Zanaboni F, Marsoni S. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464-71. [https://academic.oup.com/jnci/article-abstract/81/19/1464/952730 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2674459 PubMed]
# Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol. 1994 Oct;12(10):2066-70. [http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2066 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7931475 PubMed]
# Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J; London Gynaecological Oncology Group. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol. 1998 Jul;16(7):2426-34. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.7.2426 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9667260 PubMed]
# '''ICON2:''' Parmar MKB, Torri V, Bonaventura A, Bonazzi C, Colombo N, Delaloye JF, Marsoni S, Mangioni C, Sandercock J, Sessa C, Williams C; ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer: International Collaborative Ovarian Neoplasm Study. Lancet. 1998 Nov 14;352(9140):1571-6. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)04119-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9843101 PubMed]
# '''ICON3:''' Parmar MKB, Adams M, Balestrino M, Bertelsen K, Bonazzi C, Calvert H, Colombo N, Delaloye JF, Durando A, Guthrie D, Hagen B, Harper P, Mangioni C, Perren T, Poole C, Qian W, Rustin G, Sandercock J, Tumolo S, Torri V, Vecchione F; International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002 Aug 17;360(9332):505-15. Erratum in: Lancet. 2003 Feb 22;361(9358):706. [https://www.thelancet.com/journals/lancet/article/PIIS0140673602097386/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12241653 PubMed]
# '''SCOTROC 4:''' Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G, Lamont A, Hindley A, Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, Vasey P, Kaye SB. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol. 2013 Mar;24(3):679-87. Epub 2012 Oct 5. [https://academic.oup.com/annonc/article/24/3/679/205655 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669851/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23041585 PubMed]

==Carboplatin & Docetaxel {{#subobject:1113e0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e5c1b0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/96/22/1682.long Vasey et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Primary_debulking_surgery|Primary debulking surgery]]
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1, '''given second'''
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO twice per day the day before, the day of, and day after [[Docetaxel (Taxotere)]]
*ONE of the following 5-HT3 antagonists:
**[[Ondansetron (Zofran)]] 8 mg
**[[Granisetron]] 3 mg

'''21-day cycle for 6 cycles'''

===References===
# Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91. [http://jnci.oxfordjournals.org/content/96/22/1682.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15547181 PubMed]

==Carboplatin & Doxorubicin liposomal {{#subobject:8a720d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c48aad|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553473/ Pignata et al. 2006 (MITO-2)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Eligibility criteria for MITO-2 included: "a cytologic or histologic diagnosis of epithelial ovarian cancer (stage IC to IV according to International Federation of Gynecology and Obstetrics staging system).''
====Preceding treatment====
*[[Surgery#Primary_debulking_surgery|Primary debulking surgery]]
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1, '''given first'''
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given second'''

====Supportive medications====
*"No prophylactic use of G-CSF was recommended. Therapeutic and prophylactic use of G-CSF was allowed for febrile or afebrile grade 4 neutropenia."

'''21-day cycle for 3 to 6 cycles''' 

''All patients received 3 cycles of therapy. Patients with stable or responsive disease received an additional 3 cycles.''

===References===
# '''MITO-2:''' Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006 Aug 1;6:202. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553473/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16882344 PubMed]
## '''Update:''' Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35. Epub 2011 Aug 15. [http://jco.ascopubs.org/content/29/27/3628.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21844495 PubMed]

==Carboplatin & Gemcitabine {{#subobject:65ad86|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:dd8477|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(11)00703-7/abstract Gordon et al. 2011]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1, '''given second'''
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8, '''given first'''

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Patients with CR could optionally receive [[#Paclitaxel_monotherapy|paclitaxel consolidation]]

===References===
# Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. [http://www.gynecologiconcology-online.net/article/S0090-8258(11)00703-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21978765 PubMed]

==Carboplatin & Paclitaxel {{#subobject:dd35ee|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TC: '''<u>T</u>'''axol (Paclitaxel) & '''<u>C</u>'''arboplatin
<br>PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''arboplatin
===Variant #1, q1wk AUC 2/60 {{#subobject:1b495c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70049-X/abstract Pignata et al. 2014 (MITO-7)]
|style="background-color:#1a9851"|Phase III (E)
|TC, q3wk AUC 6/175
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV once per week
*[[Paclitaxel (Taxol)]] 60 mg/m<sup>2</sup> IV once per week

'''18-week course''' 

===Variant #2, q3wk AUC 5/175 {{#subobject:7ef902|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.17.3084 Neijt et al. 2000]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[http://jnci.oxfordjournals.org/content/96/22/1682.long Vasey et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Docetaxel|Carboplatin & Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.2938 du Bois et al. 2006 (AGO-OVAR 5)]
|style="background-color:#1a9851"|Phase III (C)
|TEC
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.09.7527 Möbus et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|High-dose chemotherapy with auto HSCT
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553473/ Pignata et al. 2006 (MITO-2)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Doxorubicin_liposomal|Carboplatin & Pegylated liposomal doxorubicin]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.27.4696 du Bois et al. 2010 (AGO-OVAR 9)]
|style="background-color:#1a9851"|Phase III (C)
|TCG
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://academic.oup.com/jnci/article/102/20/1547/964468 Hoskins et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Topotecan, then Carboplatin & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|[https://academic.oup.com/annonc/article/23/10/2613/192631 Lindemann et al. 2012]
|style="background-color:#1a9851"|Phase III (C)
|TEC
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00366-6/fulltext du Bois et al. 2015 (AGO-OVAR 12)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Nintedanib, Paclitaxel
|style="background-color:#fc8d59"|Seems to have inferior PFS
|
|-
|[https://www.ejcancer.com/article/S0959-8049(16)00072-1/fulltext Fagotti et al. 2016 (SCORPION)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_2|Neoadjuvant Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#d73027" |Inferior QoL
|-
|}
''Note: In MITO-2, all patients received 3 cycles of therapy. Patients with stable or responsive disease received an additional 3 cycles.''
====Preceding treatment====
*Neijt et al. 2000: [[Surgery#Primary_debulking_surgery|Primary debulking surgery]] was recommended
*Vasey et al. 2004, MITO-2, AGO-OVAR 12, SCORPION: [[Surgery#Primary_debulking_surgery|Primary debulking surgery]]
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1, '''given second'''
**'''MITO-2''' gave carboplatin over 30 minutes
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

====Supportive medications====
*(per Vasey et al. 2004):
*[[Dexamethasone (Decadron)]] 20 mg PO given twice, at 12 and 6 hours prior to [[Paclitaxel (Taxol)]]
*One of the following antihistamines, 30 minutes prior to [[Paclitaxel (Taxol)]]:
**[[Diphenhydramine (Benadryl)]] 50 mg IV once
**[[Chlorpheniramine (Chlor-Trimeton)]] 10 mg IV once 
*One of the following H2-blockers, 30 minutes prior to [[Paclitaxel (Taxol)]]:
**[[Ranitidine (Zantac)]] 50 mg IV once
**[[Cimetidine (Tagamet)]] 300 mg IV once 
**One of the following serotonin 5-HT3 antagonists:
**[[Ondansetron (Zofran)]] 8 mg
**[[Granisetron]] 3 mg

'''21-day cycle for 6 or more cycles (see note)'''

===Variant #3, q3wk AUC 6, q1wk 80 ("dose-dense") {{#subobject:d2604f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2961157-0/fulltext Katsumata et al. 2009 (JGOG 3016)]
|style="background-color:#1a9851"|Phase III (E)
|TC, q3wk AUC 6/180
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 60 minutes once on day 1
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15

====Supportive medications====
*"Standard premedication"

'''21-day cycle for 6 to 9 cycles, depending on response'''

===Variant #4, q3wk AUC 6/175 {{#subobject:92b591|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(08)00008-5/fulltext Alberts et al. 2008 (GRACES)]
|style="background-color:#1a9851"|Phase III (C)
|CP & IFN gamma-1b
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.9807 Lhommé et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel & Valspodar
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668552/ Bookman et al. 2009 (ICON5)]
|style="background-color:#1a9851"|Phase III (C)
|1. TC & Gemcitabine<br> 2. TC & PLD<br> 3. TC & Topotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0908806 Vergote et al. 2010 (EORTC 55971)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel|TC]] x 3, interval debulking, TC x 3
|style="background-color:#eeee01"|Non-inferior OS
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(11)00703-7/abstract Gordon et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1104390 Burger et al. 2011 (GOG-0218)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|Carboplatin, Paclitaxel, Bevacizumab]] x 6
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|Carboplatin, Paclitaxel, Bevacizumab]] x 6, then [[#Bevacizumab_monotherapy|Bev maintenance]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1103799 Perren et al. 2011 (ICON7)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|Carboplatin, Paclitaxel, Bevacizumab]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70049-X/abstract Pignata et al. 2014 (MITO-7)]
|style="background-color:#1a9851"|Phase III (C)
|TC, q1wk AUC 2/60
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00366-6/fulltext du Bois et al. 2015 (AGO-OVAR 12)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Nintedanib, Paclitaxel
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081077/ Chan et al. 2016 (GOG-0262)]
|style="background-color:#1a9851"|Phase III (C)
|TC, dose-dense
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/34/24/2881.full Sugiyama et al. 2016 (JGOG3017/GCIG)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Irinotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: reported efficacy for ICON7 is based on the 2015 update.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for up to 8 cycles'''
====Subsequent treatment====
*Gordon et al. 2011: Patients with CR could optionally proceed to receive [[#Paclitaxel_monotherapy|paclitaxel consolidation]]

===Variant #5, q3wk AUC 6/180 {{#subobject:5a09cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2961157-0/fulltext Katsumata et al. 2009 (JGOG 3016)]
|style="background-color:#1a9851"|Phase III (C)
|TC, dose-dense
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 60 minutes once on day 1
*[[Paclitaxel (Taxol)]] 180 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*"Standard premedication"

'''21-day cycle for 6 to 9 cycles, depending on response'''

===Variant #6, AUC 6/185 {{#subobject:797f8c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://academic.oup.com/jnci/article/95/17/1320/2520424 du Bois et al. 2003 (AGO-OVAR 3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
| style="background-color:#eeee01" |Non-inferior PFS
| style="background-color:#1a9850" |Superior QoL
|}
====Preceding treatment====
*[[Surgery#Primary_debulking_surgery|Primary debulking surgery]]
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 to 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 185 mg/m<sup>2</sup> (maximum dose of 400 mg) IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 6 or more cycles'''

===Variant #7, q3wk AUC 7/175 {{#subobject:b66b7b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/16/7/1116/167276 Aravantinos et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|CP/Cisplatin & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(08)00458-9/fulltext Aravantinos et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Doxorubicin, Paclitaxel
| style="background-color:#fee08b" |Might have inferior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 7 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for 6 cycles'''

===Variant #8, q3wk AUC 7.5/175 {{#subobject:8dddc3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/17/3194.long Ozols et al. 2003 (GOG 158)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
|style="background-color:#eeee01"|Seems to have non-inferior RFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 7.5 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg PO given twice, at 12 and 6 hours prior to chemotherapy OR 20 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Cimetidine (Tagamet)]] 300 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]

'''21-day cycle for 6 cycles'''

===References===
# Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3084-92. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.17.3084 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10963636 PubMed]
# '''GOG 158:''' Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14. [http://jco.ascopubs.org/content/21/17/3194.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12860964 PubMed]
# '''AGO-OVAR 3:''' du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9. [https://academic.oup.com/jnci/article/95/17/1320/2520424 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12953086 PubMed]
# Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91. [http://jnci.oxfordjournals.org/content/96/22/1682.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15547181 PubMed]
# Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos MA, Stathopoulos GP, Pavlidis N, Bafaloukos D, Papadimitriou C, Karpathios S, Georgoulias V, Papakostas P, Kalofonos HP, Grimani E, Skarlos DV; Hellenic Cooperative Oncology Group. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2005 Jul;16(7):1116-22. Epub 2005 May 31. [https://academic.oup.com/annonc/article/16/7/1116/167276 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15928071 PubMed]
<!-- # '''Abstract:''' A. du Bois, M. Combe, J. Rochon, C. Jackisch, E. Malaurie, H. J. Lueck, S. Loibl, W. Schroeder, A. Burges, and B. Weber. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial. Journal of Clinical Oncology 2004 22:14_suppl, 5007-5007 [http://ascopubs.org/doi/abs/10.1200/jco.2004.22.90140.5007 link to abstract] -->
# '''AGO-OVAR 5:''' du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E; Arbeitsgemeinschaft Gynaekologische Onkologie; Ovarian Cancer Study Group; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 2006 Mar 1;24(7):1127-35. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.2938 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16505432 PubMed]
# Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007 Sep 20;25(27):4187-93. Epub 2007 Aug 13. [http://ascopubs.org/doi/full/10.1200/JCO.2006.09.7527 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17698804 PubMed]
# '''MITO-2:''' Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006 Aug 1;6:202. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553473/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16882344 PubMed]
## '''Update:''' Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35. Epub 2011 Aug 15. [http://jco.ascopubs.org/content/29/27/3628.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21844495 PubMed]
# '''GRACES:''' Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M; GRACES Clinical Trial Consortium. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol. 2008 May;109(2):174-81. Epub 2008 Mar 7. [https://www.gynecologiconcology-online.net/article/S0090-8258(08)00008-5/fulltext link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/18314182 PubMed]
# Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008 Jun 1;26(16):2674-82. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.9807 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18509179 PubMed]
# Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, Dimopoulos MA; Hellenic Cooperative Oncology Group study. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer. 2008 Oct;44(15):2169-77. Epub 2008 Aug 6. [https://www.ejcancer.com/article/S0959-8049(08)00458-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18691879 PubMed]
# '''ICON5:''' Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305. [http://ascopubs.org/doi/10.1200/JCO.2008.19.1684 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668552/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19224846 PubMed]
# '''JGOG 3016:''' Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1331-8. Epub 2009 Sep 18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2961157-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19767092 PubMed]
## '''Update:''' Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013 Sep;14(10):1020-6. Epub 2013 Aug 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70363-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23948349 PubMed]
<!-- # '''Abstract:''' J. Herrstedt, J. Huober, F. Priou, H. Müller, M. Baekelandt, C. Kurzeder, J. Pfisterer, A. Stähle, I. Ray-Coquard, and A. du Bois. A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients. Journal of Clinical Oncology 2009 27:18S, LBA5510-LBA5510 [http://ascopubs.org/doi/abs/10.1200/jco.2009.27.18s.lba5510 link to abstract] -->
# '''AGO-OVAR 9:''' du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010 Sep 20;28(27):4162-9. Epub 2010 Aug 23. [http://ascopubs.org/doi/full/10.1200/JCO.2009.27.4696 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20733132 PubMed]
# '''EORTC 55971:''' Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. [https://www.nejm.org/doi/full/10.1056/NEJMoa0908806 link to original article] '''contains protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/20818904 PubMed]
# Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst. 2010 Oct 20;102(20):1547-56. Epub 2010 Oct 11. [https://academic.oup.com/jnci/article/102/20/1547/964468 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20937992 PubMed]
# Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. [http://www.gynecologiconcology-online.net/article/S0090-8258(11)00703-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21978765 PubMed]
# '''GOG-0218:''' Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. [https://www.nejm.org/doi/full/10.1056/NEJMoa1104390 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22204724 PubMed]
# '''ICON7:''' Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. [https://www.nejm.org/doi/full/10.1056/NEJMoa1103799 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22204725 PubMed]
## '''Update:''' Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928-36. Epub 2015 Jun 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00086-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648090/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26115797 PubMed]
# Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol. 2012 Oct;23(10):2613-9. Epub 2012 Apr 26. [https://academic.oup.com/annonc/article/23/10/2613/192631 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22539562 PubMed]
<!-- # '''Abstract:''' Sandro Pignata, Giovanni Scambia, Rossella Lauria, Francesco Raspagliesi, Pierluigi Benedetti Panici, Gennaro Cormio, Dionyssios Katsaros, Roberto Sorio, Giovanna Cavazzini, Gabriella Ferrandina, Enrico Breda, Viviana Murgia, Cosimo Sacco, Nuria Maria Asensio Sierra, Carmela Pisano, Vanda Salutari, Beatrice E. Weber, Eric Pujade-Lauraine, Ciro Gallo, Francesco Perrone. A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)—European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. 2013 ASCO Annual Meeting abstract LBA5501. [http://meetinglibrary.asco.org/content/112845-132 link to abstract] -->
# '''MITO-7:''' Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014 Apr;15(4):396-405. Epub 2014 Feb 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70049-X/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24582486 PubMed]
# '''CHORUS:''' Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249-57. Epub 2015 May 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62223-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26002111/ PubMed]
# '''AGO-OVAR 12:''' du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89. Epub 2015 Nov 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00366-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26590673 PubMed]
# '''GOG-0262:''' Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738-48. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505067 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081077/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26933849 PubMed]
# '''SCORPION:''' Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016 May;59:22-33. Epub 2016 Mar 19. [https://www.ejcancer.com/article/S0959-8049(16)00072-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26998845 PubMed]
<!-- Presented at the 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2014. -->
# '''JGOG3017:''' Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol. 2016 Aug 20;34(24):2881-7. Epub 2016 Jul 11. [http://jco.ascopubs.org/content/34/24/2881.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27400948 PubMed]

==Carboplatin, Paclitaxel, Bevacizumab {{#subobject:8d896f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TC-BEV: '''<u>T</u>'''axol (Paclitaxel), '''<u>C</u>'''arboplatin, '''<u>BEV</u>'''acizumab
===Variant #1, standard-dose bevacizumab {{#subobject:12e241|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1104390 Burger et al. 2011 (GOG-0218)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
|style="background-color:#1a9850"|Superior PFS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081077/ Chan et al. 2016 (GOG-0262)]
|style="background-color:#1a9851"|Phase III (C)
|TC-Bev, dose-dense
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: superior efficacy in GOG-0218 was only demonstrated in the arm that went on to receive [[#Bevacizumab_monotherapy|bevacizumab maintenance]]. Decision to use bevacizumab in GOG-0262 was at the discretion of the patient; it was not a randomization.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
*[[Bevacizumab (Avastin)]] as follows:
**Cycle 1: none
**Cycles 2 to 6: 15 mg/kg IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*GOG-0218: No further treatment versus [[#Bevacizumab_monotherapy|bevacizumab maintenance]]
*GOG-0262: [[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===Variant #2, low-dose bevacizumab {{#subobject:be6ac3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1103799 Perren et al. 2011 (ICON7)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|}
''Note: reported efficacy is based on the 2015 update.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 to 6 IV over 30 to 60 minutes once on day 1
**The protocol linked from Perren et al. 2011 clarifies that the recommended dose was AUC 6, but that it could be adjusted per standard practice
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
*[[Bevacizumab (Avastin)]] as follows:
**Cycle 1: not given if chemotherapy starts within 4 weeks of surgery. If greater than 4 weeks after surgery: 7.5 mg/kg IV once on day 1
**Cycles 2 to 6: 7.5 mg/kg IV once on day 1

'''21-day cycle for 6 cycles'''

====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===References===
# '''GOG-0218:''' Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. [https://www.nejm.org/doi/full/10.1056/NEJMoa1104390 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22204724 PubMed]
# '''ICON7:''' Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. [https://www.nejm.org/doi/full/10.1056/NEJMoa1103799 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22204725 PubMed]
## '''Update:''' Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928-36. Epub 2015 Jun 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00086-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648090/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26115797 PubMed]
# '''GOG-0262:''' Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738-48. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505067 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081077/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26933849 PubMed]

==Cisplatin & Paclitaxel {{#subobject:d05939|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TP: '''<u>T</u>'''axol (Paclitaxel) & '''<u>P</u>'''latinol (Cisplatin)
<br>PT: '''<u>P</u>'''latinol (Cisplatin) & '''<u>T</u>'''axol (Paclitaxel)
===Variant #1, 75/135 {{#subobject:69d2c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199601043340101 McGuire et al. 1996 (GOG 111)]
|style="background-color:#1a9851"|Phase III (E)
|[[Ovarian_cancer_-_historical#Cisplatin_.26_Cyclophosphamide_2|Cisplatin & Cyclophosphamide]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.1.106 Muggia et al. 2000 (GOG 132)]
|style="background-color:#1a9851"|Phase III (C)
|1. Cisplatin<br> 2. Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.4.1001 Markman et al. 2001 (GOG 114)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, IP Cisplatin
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/21/17/3194.long Ozols et al. 2003 (GOG 158)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
|style="background-color:#eeee01"|Seems to have non-inferior RFS
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa041125 Rose et al. 2004 (GOG 152)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Paclitaxel, with interval debulking
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052985 Armstrong et al. 2006 (GOG 172)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Paclitaxel_2|IP Cisplatin & Paclitaxel]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.10.3846 Spriggs et al. 2007 (GOG 162)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & prolonged-infusion Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*GOG 111, 132, 152: [[Surgery#Primary_debulking_surgery|Primary debulking surgery]], with subotpimal debulking
*GOG 114, 158, 172: [[Surgery#Primary_debulking_surgery|Primary debulking surgery]], with optimal debulking
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
**Some regimens give the cisplatin '''after''' the paclitaxel (i.e., on day 2)
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV continuous infusion over 24 hours once on day 1

====Supportive medications====
*(details vary depending on reference):
*[[Dexamethasone (Decadron)]] 20 mg PO given twice, at 12 and 6 hours prior to chemotherapy OR 20 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Cimetidine (Tagamet)]] 300 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
*"Hydration and [[:Category:Emesis_prevention|antiemetic agents]]" before [[Cisplatin (Platinol)]]

'''21-day cycle for 6 cycles'''

===Variant #2, 75/175 {{#subobject:61acf0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article/92/9/699/2906130 Piccart et al. 2000 (OV10)]
|style="background-color:#1a9851"|Phase III (E)
|[[Ovarian_cancer_-_historical#Cisplatin_.26_Cyclophosphamide_2|Cisplatin & Cyclophosphamide]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.17.3084 Neijt et al. 2000]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ar.iiarjournals.org/content/27/1B/681.long Mouratidou et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|[[Ovarian_cancer_-_historical#Cisplatin_.26_Cyclophosphamide_2|Cisplatin & Cyclophosphamide]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(14)00815-6/fulltext van der Burg et al. 2014]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & weekly Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|}
====Preceding treatment====
*OV10: [[Surgery#Primary_debulking_surgery|Primary debulking surgery]], with optimal or suboptimal debulking
*Neijt et al. 2000: [[Surgery#Primary_debulking_surgery|Primary debulking surgery]] was recommended
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 6 or more cycles'''

===Variant #3, 75/185 {{#subobject:ca46db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://academic.oup.com/jnci/article/95/17/1320/2520424 du Bois et al. 2003 (AGO-OVAR 3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]]
| style="background-color:#eeee01" |Non-inferior PFS
| style="background-color:#d73027" |Inferior QoL
|}
====Preceding treatment====
*[[Surgery#Primary_debulking_surgery|Primary debulking surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> (maximum dose of 165 mg) IV over 30 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 185 mg/m<sup>2</sup> (maximum dose of 400 mg) IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 6 or more cycles'''

===References===
# '''GOG 111:''' McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1-6. [https://www.nejm.org/doi/full/10.1056/NEJM199601043340101 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7494563 PubMed]
# '''GOG 132:''' Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000 Jan;18(1):106-15. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.1.106 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10623700 PubMed]
# '''OV10:''' Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000 May 3;92(9):699-708. [https://academic.oup.com/jnci/article/92/9/699/2906130 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10793106 PubMed]
# Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3084-92. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.17.3084 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10963636 PubMed]
# '''GOG 114:''' Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.4.1001 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11181662 PubMed]
# '''GOG 158:''' Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14. [http://jco.ascopubs.org/content/21/17/3194.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12860964 PubMed]
# '''AGO-OVAR 3:''' du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9. [https://academic.oup.com/jnci/article/95/17/1320/2520424 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12953086 PubMed]
# '''GOG 152:''' Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004 Dec 9;351(24):2489-97. [https://www.nejm.org/doi/10.1056/NEJMoa041125 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15590951 PubMed]
# '''GOG 172:''' Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa052985 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16394300 PubMed]
## '''Subgroup analysis:''' Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan;100(1):27-32. [http://www.gynecologiconcology-online.net/article/S0090-8258(05)01001-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16368440 PubMed]
# Mouratidou D, Gennatas C, Michalaki V, Papadimitriou A, Andreadis CH, Sykiotis C, Tsavaris N. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Res. 2007 Jan-Feb;27(1B):681-5. [http://ar.iiarjournals.org/content/27/1B/681.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17348460 PubMed]
# '''GOG 162:''' Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Oct 1;25(28):4466-71. [http://ascopubs.org/doi/full/10.1200/JCO.2006.10.3846 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17906207 PubMed]
# van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. Eur J Cancer. 2014 Oct;50(15):2592-601. Epub 2014 Aug 2. [https://www.ejcancer.com/article/S0959-8049(14)00815-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25096168 PubMed]

=Intraperitoneal therapy=
==Cisplatin & Paclitaxel {{#subobject:cf7ed4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e9c475|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052985 Armstrong et al. 2006 (GOG 172)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Paclitaxel|IV Cisplatin & Paclitaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IP rapid infusion once on day 2
**Walker et al. 2006 instructs that the patient be rolled onto 4 different positions every 15 minutes to evenly distribute cisplatin
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV continuous infusion over 24 hours once on day 1, then 60 mg/m<sup>2</sup> IP rapid infusion once on day 8

====Supportive medications====
*(Varies per reference)
*"Standard premedication" for [[Paclitaxel (Taxol)]]
*"Hydration and [[:Category:Emesis_prevention|antiemetic agents]]" before [[Cisplatin (Platinol)]]
*Intraperitoneal doses of cisplatin and paclitaxel are reconstituted in 2 liters of warm normal saline before infusion
*Additional 1 liter normal saline to be infused immediately after intraperitoneal [[Paclitaxel (Taxol)]]
*Supportive medications left to investigator discretion

'''21-day cycle for 6 cycles'''

===References===
# '''GOG 172:''' Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa052985 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16394300 PubMed]
## '''Subgroup analysis:''' Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan;100(1):27-32. [http://www.gynecologiconcology-online.net/article/S0090-8258(05)01001-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16368440 PubMed]

=Maintenance after first-line therapy=
==Altretamine monotherapy {{#subobject:fb91d1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:284dfe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(01)96274-2/pdf Rothenberg et al. 2001 (SWOG-9326)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Altretamine (Hexalen)]] 260 mg/m<sup>2</sup>/day PO on days 1 to 14, split into 4 daily doses

'''28-day cycles for 6 months'''

===References===
# Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol. 2001 Aug;82(2):317-22. [http://www.gynecologiconcology-online.net/article/S0090-8258(01)96274-2/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11531286 PubMed]
## '''Update:''' Alberts DS, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer. 2004 Mar-Apr;14(2):224-8. [https://www.ncbi.nlm.nih.gov/pubmed/15086720 PubMed]

==Bevacizumab monotherapy {{#subobject:1d2514|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 12 cycles {{#subobject:327e14|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1103799 Perren et al. 2011 (ICON7)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|Carboplatin, Paclitaxel, Bevacizumab]] x 6
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 12 cycles'''

===Variant #2, 16 cycles {{#subobject:a87d26|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1104390 Burger et al. 2011 (GOG-0218)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. The FDA-recommended duration of treatment is 22 cycles (including the 6 cycles of combination chemotherapy).''
====Preceding treatment====
*[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|Carboplatin, Paclitaxel, Bevacizumab]] x 6
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 16 cycles'''

===Variant #3, indefinite {{#subobject:dbffb6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081077/ Chan et al. 2016 (GOG-0262)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|Carboplatin, Paclitaxel, Bevacizumab]] x 6
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''
===References===
# '''GOG-0218:''' Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. [https://www.nejm.org/doi/full/10.1056/NEJMoa1104390 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22204724 PubMed]
# '''ICON7:''' Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. [https://www.nejm.org/doi/full/10.1056/NEJMoa1103799 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22204725 PubMed]
## '''Update:''' Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928-36. Epub 2015 Jun 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00086-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648090/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26115797 PubMed]
# '''GOG-0262:''' Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738-48. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505067 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081077/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26933849 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://insights.ovid.com/pubmed?pmid=14656280 Piccart et al. 2003 (EORTC 55875)]
|style="background-color:#1a9851"|Phase III (C)
|IP Cisplatin
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.09.088 De Placido et al. 2004 (MITO-1)]
|style="background-color:#1a9851"|Phase III (C)
|Topotecan
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364769/ Hall et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|IFN alfa-2a
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/jnci/article/98/15/1036/2521688 Pfisterer et al. 2006 (AGO-OVAR 7)]
|style="background-color:#1a9851"|Phase III (C)
|Topotecan
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.8400 Berek et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Oregovomab
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9691 Pecorelli et al. 2009 (After-6 protocol 1)]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.50.5669 Vergote et al. 2013 (EORTC 55041)]
|style="background-color:#1a9851"|Phase III (C)
|Erlotinib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further treatment.''
====Preceding treatment====
*AGO-OVAR 7: [[#Carboplatin_.26_Paclitaxel_3|TC]] x 6-10
*EORTC 55041: Debulking surgery (primary or interval) & platinum-based chemotherapy x 6 to 9, with SD or better

===References===
# '''EORTC 55875:''' Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, Giurgea L, Coens C, Awada A, Vermorken JB. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203. [https://insights.ovid.com/pubmed?pmid=14656280 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14656280 PubMed]
# '''MITO-1:''' De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004 Jul 1;22(13):2635-42. [http://ascopubs.org/doi/full/10.1200/JCO.2004.09.088 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15226331 PubMed]
# Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, Poole C, Crawford M, Hancock B, Selby PJ, Perren TJ. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer. 2004 Aug 16;91(4):621-6. [https://www.nature.com/articles/6602037 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364769/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/15305182 PubMed]
# '''AGO-OVAR 7:''' Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45. [https://academic.oup.com/jnci/article/98/15/1036/2521688 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16882940 PubMed]
# Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27(3):418-25. Epub 2008 Dec 15. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.8400 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19075271 PubMed]
# '''After-6 protocol 1:''' Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P; After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009 Oct 1;27(28):4642-8. Epub 2009 Aug 24. [http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9691 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19704064 PubMed]
<!-- Presented as an oral abstract at the 48th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2012. -->
# '''EORTC 55041:''' Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol. 2014 Feb 1;32(4):320-6. Epub 2013 Dec 23. [http://ascopubs.org/doi/full/10.1200/JCO.2013.50.5669 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24366937 PubMed]

==Olaparib monotherapy {{#subobject:fac248|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8a3c0d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1810858 Moore et al. 2018 (SOLO-1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Patients had BRCA1/2 mutations.''
====Chemotherapy====
*[[Olaparib (Lynparza)]] 300 mg PO twice per day

'''Continued indefinitely'''
===References===
# '''SOLO-1:''' Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 Oct 21. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1810858 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30345884 PubMed]

==Paclitaxel monotherapy {{#subobject:6f7a6a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 135 mg/m<sup>2</sup> q4wk {{#subobject:b5e4cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(11)00703-7/abstract Gordon et al. 2011]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]] x 6 versus [[#Carboplatin_.26_Paclitaxel_3|Carboplatin & Paclitaxel]] x 6
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 12 cycles'''

===Variant #2, 175 mg/m<sup>2</sup> q3wk x 3 {{#subobject:5bb98c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(04)00809-1/abstract Micha et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|}
====Preceding treatment====
*Carboplatin, Gemcitabine, Paclitaxel x 6
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for 3 cycles'''

===Variant #3, 175 mg/m<sup>2</sup> q3wk x 12 {{#subobject:7d827f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(04)00809-1/abstract Micha et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|}
====Preceding treatment====
*Carboplatin, Gemcitabine, Paclitaxel x 6
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for 12 cycles'''

===Variant #4, 175 mg/m<sup>2</sup> q4wk x 3 {{#subobject:b29e5b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/13/2460.long Markman et al. 2003 (GOG 178)]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel for 12 cycles
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''28-day cycle for 3 cycles'''

===Variant #5, 175 mg/m<sup>2</sup> q4wk x 12 {{#subobject:dff428|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/13/2460.long Markman et al. 2003 (GOG 178)]
|style="background-color:#1a9851"|Phase III (E)
|Paclitaxel for 3 cycles
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''28-day cycle for 12 cycles'''

===References===
# Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D; Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003 Jul 1;21(13):2460-5. [http://jco.ascopubs.org/content/21/13/2460.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12829663 PubMed]
## '''Update:''' Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m<sup>2</sup>) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009 Aug;114(2):195-8. Epub 2009 May 17. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744303 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744303/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19447479 PubMed]
# Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol. 2005 Jan;96(1):132-5. [http://www.gynecologiconcology-online.net/article/S0090-8258(04)00809-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15589591 PubMed]
# '''Retrospective:''' Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV 3rd, Markman M. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology. 2010;78(5-6):389-93. Epub 2010 Aug 27. [http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&ArtikelNr=000320579&Ausgabe=254415&ProduktNr=223857 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20798562 PubMed]
# Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. [http://www.gynecologiconcology-online.net/article/S0090-8258(11)00703-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21978765 PubMed]

==Pazopanib monotherapy {{#subobject:84efa4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a0ac84|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/30/3374.long Du Bois et al. 2014 (AGO-OVAR 16)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Patients enrolled in AGO-OVAR 16 had histologically confirmed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, were FIGO II to IV, and no evidence of progression after initial treatment.''
====Preceding treatment====
*[[Surgery#Ovarian_cancer_surgery|Surgery]] and at least 5 cycles of platinum and taxane combination chemotherapy

====Chemotherapy====
*[[Pazopanib (Votrient)]] 800 mg PO once per day

'''24-month course'''

===References===
<!-- # '''Abstract:''' Andreas Du Bois, Anne Floquet, Jae Weon Kim, Jörn Rau, Jose Maria Del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Mansoor Raza Mirza, Bradley J. Monk, Pauline Wimberger, Isabelle Ray-Coquard, Rongyu Zang, Ivan Diaz-Padilla, Klaus H. Baumann, Jae Hoon Kim, Philipp Harter. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). 2013 ASCO Annual Meeting abstract LBA5503. [http://meetinglibrary.asco.org/content/115898-132 link to abstract] -->
# '''AGO-OVAR 16:''' du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. [http://jco.ascopubs.org/content/32/30/3374.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25225436 PubMed]
## '''Subgroup analysis:''' Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. [https://journals.lww.com/ijgc/Abstract/2018/01000/Pazopanib_Maintenance_Therapy_in_East_Asian_Women.2.aspx link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26588236 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(05)01122-4/fulltext Hirte et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|Tanomastat
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795662/ Sabbatini et al. 2013 (MIMOSA)]
|style="background-color:#1a9851"|Phase III (C)
|Abagovomab
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/32/30/3374.long Du Bois et al. 2014 (AGO-OVAR 16)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pazopanib_monotherapy|Pazopanib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''No active antineoplastic treatment after initial treatment.''
====Preceding treatment====
*MIMOSA: Debulking surgery, then platinum-taxane-based chemotherapy x 6 to 8, with CR
*AGO-OVAR 16: Debulking surgery (primary or interval) & platinum-taxane-based chemotherapy for at least 5 cycles, with SD or better

===References===
# Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006 Aug;102(2):300-8. Epub 2006 Jan 25. [https://www.gynecologiconcology-online.net/article/S0090-8258(05)01122-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16442153 PubMed]
# '''MIMOSA:''' Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013 Apr 20;31(12):1554-61. Epub 2013 Mar 11. [http://ascopubs.org/doi/full/10.1200/JCO.2012.46.4057 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795662/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23478059 PubMed]
<!-- # '''Abstract:''' Andreas Du Bois, Anne Floquet, Jae Weon Kim, Jörn Rau, Jose Maria Del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Mansoor Raza Mirza, Bradley J. Monk, Pauline Wimberger, Isabelle Ray-Coquard, Rongyu Zang, Ivan Diaz-Padilla, Klaus H. Baumann, Jae Hoon Kim, Philipp Harter. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). 2013 ASCO Annual Meeting abstract LBA5503. [http://meetinglibrary.asco.org/content/115898-132 link to abstract] -->
# '''AGO-OVAR 16:''' du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. [http://jco.ascopubs.org/content/32/30/3374.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25225436 PubMed]
## '''Subgroup analysis:''' Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. [https://journals.lww.com/ijgc/Abstract/2018/01000/Pazopanib_Maintenance_Therapy_in_East_Asian_Women.2.aspx link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26588236 PubMed]

=Second-line therapy for relapsed or recurrent disease, platinum-sensitive=

==Carboplatin monotherapy {{#subobject:f19c03|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, AUC 5 {{#subobject:34cc91|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2913718-X/fulltext Parmar et al. 2003 (ICON4)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]<br> 2. [[#Cisplatin_.26_Paclitaxel_3|Cisplatin & Paclitaxel]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/24/29/4699.long Pfisterer et al. 2006 (AGO-OVAR 2.5)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Gemcitabine_2|Carboplatin & Gemcitabine]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1

'''21-day cycle for 6 to 10 cycles'''

===Variant #2, 300 mg/m<sup>2</sup> {{#subobject:85cc91|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(01)96151-7/pdf Bolis et al. 2001 (ARGO 96)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin & Epirubicin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] 300 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 5 cycles'''

===References===
# '''ARGO 96:''' Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F; Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 2001 Apr;81(1):3-9. [https://www.gynecologiconcology-online.net/article/S0090-8258(01)96151-7/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11277642 PubMed]
# '''ICON4:''' Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2913718-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12826431 PubMed]
<!-- Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004 and at the 10th Biennial Meeting of the International Gynecologic Cancer Society, Edinburgh, Scotland, October 3-7, 2004. -->
# '''AGO-OVAR 2.5:''' Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11. [http://jco.ascopubs.org/content/24/29/4699.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16966687 PubMed]

==Carboplatin & Docetaxel {{#subobject:8cd1bc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, AUC 2/35, 3 weeks out of 4 {{#subobject:bd8ef9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(06)01017-1/abstract Kushner et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: BSA was capped at 2 m<sup>2</sup>.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV over 30 minutes once per day on days 1, 8, 15, '''given second'''
*[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> (maximum dose of 70 mg) IV over 60 minutes once per day on days 1, 8, 15, '''given first'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 4 mg PO the evening before, the morning of, and evening after [[Docetaxel (Taxotere)]]
*[[:Category:Serotonin 5-HT3 antagonists|5-HT3 antagonist]] before chemotherapy
*[[:Category:Phenothiazines|Phenothiazine]] or [[:Category:Serotonin 5-HT3 antagonists|5-HT3 antagonist]] as needed as an outpatient
*[[Diphenhydramine (Benadryl)]] 50 mg IV once immediately prior to [[Docetaxel (Taxotere)]]

'''28-day cycle for 6 cycles'''

===Variant #2, AUC 5/75 {{#subobject:9c8b3f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(06)00790-6/abstract Strauss et al. 2007]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.63.2596 Vergote et al. 2016 (MORAb-003-004)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Docetaxel, Farletuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is the lower bound of carboplatin dosing specified by MORAb-003-004.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 to 60 minutes once on day 1, '''given second'''
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''

====Supportive medications====
*[[:Category:Steroids|Corticosteroids]] given twice, 12 hours and 30 minutes before [[Docetaxel (Taxotere)]]
*Prophylactic [[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]]

'''21-day cycle for 6 cycles'''

===Variant #3, AUC 6/75 {{#subobject:91cb64|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.63.2596 Vergote et al. 2016 (MORAb-003-004)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Farletuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is the upper bound of carboplatin dosing specified by MORAb-003-004.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''
===References===
# Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol. 2007 Mar;104(3):612-6. Epub 2006 Oct 27. [http://www.gynecologiconcology-online.net/article/S0090-8258(06)00790-6/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17069876 PubMed]
# Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM; Wisconsin Oncology Network. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007 May;105(2):358-64. Epub 2007 Jan 29. [http://www.gynecologiconcology-online.net/article/S0090-8258(06)01017-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17258800 PubMed]
# '''MORAb-003-004:''' Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O'Shannessy D, Herzog TJ. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016 Jul 1;34(19):2271-8. Epub 2016 Mar 21. [http://ascopubs.org/doi/full/10.1200/JCO.2015.63.2596 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27001568 PubMed]

==Carboplatin & Doxorubicin liposomal {{#subobject:a277bb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CD: '''<u>C</u>'''arboplatin & '''<u>D</u>'''oxil (Pegylated liposomal doxorubicin)
<br>PLDC: '''<u>P</u>'''egylated '''<u>L</u>'''iposomal '''<u>D</u>'''oxorubicin & '''<u>C</u>'''arboplatin
===Regimen {{#subobject:b45db0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/20/3323.long Pujade-Lauraine et al. 2010 (CALYPSO)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|[https://academic.oup.com/annonc/article/27/12/2236/2354560 Sehouli et al. 2016 (HECTOR)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Carboplatin & Topotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|}
CALYPSO: '''<u>Ca</u>'''e'''<u>ly</u>'''x (Pegylated liposomal doxorubicin) in '''<u>P</u>'''latinum '''<u>S</u>'''ensitive '''<u>O</u>'''varian patients
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*"Antiemetics, including a [[:Category:Serotonin 5-HT3 antagonists|serotonin 5-HT3 antagonist]] and [[:Category:Steroids|corticosteroid]]"

'''28-day cycle for 6 or more cycles, depending on response and toxicity'''

===References===
<!-- Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2009, Orlando, FL. -->
# '''CALYPSO:''' Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24. [http://jco.ascopubs.org/content/28/20/3323.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20498395 PubMed]
## '''Update:''' Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91. Epub 2012 Jul 26. [https://www.nature.com/bjc/journal/v107/n4/full/bjc2012307a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419956/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22836511 PubMed]
# '''HECTOR:''' Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016 Dec;27(12):2236-2241. Epub 2016 Oct 26. [https://academic.oup.com/annonc/article/27/12/2236/2354560 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27789470 PubMed]

==Carboplatin & Gemcitabine {{#subobject:512563|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''arboplatin
===Variant #1, limited duration {{#subobject:adfc3c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/29/4699.long Pfisterer et al. 2006 (AGO-OVAR 2.5)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_monotherapy_2|Carboplatin]]
|style="background-color:#1a9850"|Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646321/ Aghajanian et al. 2012 (OCEANS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Gemcitabine.2C_Bevacizumab|Carboplatin, Gemcitabine, Bevacizumab]], then [[#Bevacizumab_monotherapy_2|Bev maintenance]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 6 to 10 cycles'''

===Variant #2, indefinite {{#subobject:4d43df|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/27/12/2236/2354560 Sehouli et al. 2016 (HECTOR)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Carboplatin & Topotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''
===References===
<!-- Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004 and at the 10th Biennial Meeting of the International Gynecologic Cancer Society, Edinburgh, Scotland, October 3-7, 2004. -->
# '''AGO-OVAR 2.5:''' Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11. [http://jco.ascopubs.org/content/24/29/4699.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16966687 PubMed]
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL. -->
# Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23. [http://jco.ascopubs.org/content/30/17/2039.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646321/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22529265 PubMed]
## '''Update:''' Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015 Oct;139(1):10-6. Epub 2015 Aug 10. [http://www.gynecologiconcology-online.net/article/S0090-8258(15)30098-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993045/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26271155 PubMed]
# Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016 Dec;27(12):2236-2241. Epub 2016 Oct 26. [https://academic.oup.com/annonc/article/27/12/2236/2354560 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27789470 PubMed]

==Carboplatin, Gemcitabine, Bevacizumab {{#subobject:d73384|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bc0424|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646321/ Aghajanian et al. 2012 (OCEANS)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#OCEANS|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#OCEANS|See link]]
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1, '''given first'''

'''21-day cycle for 6 to 10 cycles, based on response''' 
====Subsequent treatment====
*[[#Bevacizumab_monotherapy_2|Bevacizumab maintenance]]

===References===
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL. -->
# Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23. [http://jco.ascopubs.org/content/30/17/2039.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646321/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22529265 PubMed]
## '''Update:''' Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015 Oct;139(1):10-6. Epub 2015 Aug 10. [http://www.gynecologiconcology-online.net/article/S0090-8258(15)30098-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993045/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26271155 PubMed]

==Carboplatin & Paclitaxel {{#subobject:f8f27a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP: '''<u>C</u>'''arboplatin & '''<u>P</u>'''aclitaxel
<br>PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''arboplatin
===Variant #1, AUC 5/175, limited duration {{#subobject:9bef30|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.63.2596 Vergote et al. 2016 (MORAb-003-004)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Farletuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30279-6/fulltext Coleman et al. 2017 (NRG/GOG-0213)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Bevacizumab
|style="background-color:#fee08b"|Might have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.73.4293 Pignata et al. 2017 (MITO-8)]
|style="background-color:#1a9851"|Phase III (C)
|NPBC
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*(varies depending on reference):
*[[:Category:Steroids|Corticosteroids]] and prophylactic [[:Category:Serotonin 5-HT3 antagonists|5-HT3 antagonist]]
*Premedication (with steroids & antihistamines) prior to [[Paclitaxel (Taxol)]]

'''21-day cycle for 6 to 9 cycles'''
====Subsequent treatment====
*MITO-8, upon progression: Non-platinum-based chemotherapy (NPBC)

===Variant #2, AUC 5/175, indefinite {{#subobject:f36665|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2913718-X/fulltext Parmar et al. 2003 (ICON4)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_monotherapy_2|Carboplatin]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/28/20/3323.long Pujade-Lauraine et al. 2010 (CALYPSO)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Doxorubicin_liposomal_2|Carboplatin & PLD]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/abstract Oza et al. 2014 (D0810C00041)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Carboplatin.2C_Olaparib.2C_Paclitaxel.2C|Carboplatin, Olaparib, Paclitaxel]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://academic.oup.com/annonc/article/27/12/2236/2354560 Sehouli et al. 2016 (HECTOR)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Carboplatin & Topotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30279-6/fulltext Coleman et al. 2017 (NRG/GOG-0213)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Bevacizumab
|style="background-color:#fee08b"|Might have inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*(varies depending on reference):
*[[:Category:Steroids|Corticosteroids]] and prophylactic [[:Category:Serotonin 5-HT3 antagonists|5-HT3 antagonist]]
*Premedication (with steroids & antihistamines) prior to [[Paclitaxel (Taxol)]]

'''21-day cycles'''

===Variant #3, AUC 6/175, limited duration {{#subobject:626b9d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.63.2596 Vergote et al. 2016 (MORAb-003-004)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Farletuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for 6 cycles'''

===Variant #4, AUC 6/175, indefinite {{#subobject:d9fae9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/abstract Oza et al. 2014 (D0810C00041)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Carboplatin.2C_Olaparib.2C_Paclitaxel.2C|Carboplatin, Olaparib, Paclitaxel]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*(varies depending on reference):
*[[:Category:Steroids|Corticosteroids]] and prophylactic [[:Category:Serotonin 5-HT3 antagonists|5-HT3 antagonist]]
*Premedication (with steroids & antihistamines) prior to [[Paclitaxel (Taxol)]]

'''21-day cycles'''

===References===
# '''ICON4:''' Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2913718-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12826431 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2009, Orlando, FL. -->
# '''CALYPSO:''' Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24. [http://jco.ascopubs.org/content/28/20/3323.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20498395 PubMed]
## '''Update:''' Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91. Epub 2012 Jul 26. [https://www.nature.com/bjc/journal/v107/n4/full/bjc2012307a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419956/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22836511 PubMed]
# '''D0810C00041:''' Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25481791 PubMed]
# '''MORAb-003-004:''' Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O'Shannessy D, Herzog TJ. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016 Jul 1;34(19):2271-8. Epub 2016 Mar 21. [http://ascopubs.org/doi/full/10.1200/JCO.2015.63.2596 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27001568 PubMed]
# '''HECTOR:''' Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016 Dec;27(12):2236-2241. Epub 2016 Oct 26. [https://academic.oup.com/annonc/article/27/12/2236/2354560 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27789470 PubMed]
# '''NRG/GOG-0213:''' Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-791. Epub 2017 Apr 21. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30279-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28438473 PubMed]
# '''MITO-8:''' Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Piccirillo MC, Gallo C, Perrone F. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study. J Clin Oncol. 2017 Oct 10;35(29):3347-3353. Epub 2017 Aug 21. [http://ascopubs.org/doi/full/10.1200/JCO.2017.73.4293 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28825853 PubMed]

==Carboplatin, Olaparib, Paclitaxel {{#subobject:5c058c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5d64f2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/abstract Oza et al. 2014 (D0810C00041)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 IV once on day 1
*[[Olaparib (Lynparza)]] 200 mg PO twice per day on days 1 to 10
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Olaparib_monotherapy_3|Olaparib maintenance]]

===References===
# '''D0810C00041:''' Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25481791 PubMed]

==Cisplatin & Gemcitabine {{#subobject:b8b04f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:375811|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(02)96850-2/abstract Rose et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8, given second
*[[Gemcitabine (Gemzar)]] 750 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8, given first

====Supportive medications====
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonists]]
*[[:Category:Steroids|Corticosteroids]]
*[[Prochlorperazine (Compazine)]]
*Magnesium supplementation with [[Cisplatin (Platinol)]]

'''21-day cycles'''

===References===
# Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 2003 Jan;88(1):17-21. [http://www.gynecologiconcology-online.net/article/S0090-8258(02)96850-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12504621 PubMed]

==Cisplatin & Paclitaxel {{#subobject:610ae9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8149f0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2913718-X/fulltext Parmar et al. 2003 (ICON4)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_monotherapy_2|Carboplatin]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycles'''

===References===
# '''ICON4:''' Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2913718-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12826431 PubMed]

==Etoposide monotherapy {{#subobject:a7d95b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:98f6b8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/16/2/405.long Rose et al. 1998]
|style="background-color:#91cf61"|Phase II
|ORR: 34%
|-
|}
====Chemotherapy====
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 21
**Dosage for patients with previous pelvic radiation: 30 mg/m<sup>2</sup> PO once per day on days 1 to 21; dose could be increased up to 50 mg/m<sup>2</sup> depending on toxicity

'''28-day cycles'''

===References===
# Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10. [http://jco.ascopubs.org/content/16/2/405.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9469322 PubMed]

==Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:3eae7f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f597f1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/27/9/1426.long Teneriello et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 260 mg/m<sup>2</sup> IV over 30 minutes once on day 1

'''21-day cycle for 6 to 8 cycles'''

===References===
# Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2009 Mar 20;27(9):1426-31. Epub 2009 Feb 17. [http://jco.ascopubs.org/content/27/9/1426.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19224848 PubMed]

==Rucaparib monotherapy {{#subobject:72fd0c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:68aa39|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30559-9/abstract Swisher et al. 2016 (ARIEL2 Part 1)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rucaparib (Rubraca)]] 600 mg PO twice per day

'''28-day cycles'''

===References===
# '''ARIEL2 Part 1:''' Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 Jan;18(1):75-87. Epub 2016 Nov 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30559-9/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27908594 PubMed]

=Maintenance after second-line therapy for platinum-sensitive disease=

==Bevacizumab monotherapy {{#subobject:f055de|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:4e53f3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646321/ Aghajanian et al. 2012 (OCEANS)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#OCEANS|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#OCEANS|See link]]
|-
|}
====Preceding treatment====
*[[#Carboplatin.2C_Gemcitabine.2C_Bevacizumab|GC & Bevacizumab]] x 6 to 10 cycles
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL. -->
# Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23. [http://jco.ascopubs.org/content/30/17/2039.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646321/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22529265 PubMed]
## '''Update:''' Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015 Oct;139(1):10-6. Epub 2015 Aug 10. [http://www.gynecologiconcology-online.net/article/S0090-8258(15)30098-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993045/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26271155 PubMed]

==Niraparib monotherapy {{#subobject:eb98d9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:faee66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1611310 Mirza et al. 2016 (NOVA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_2|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*Platinum-containing chemotherapy; neither specific agents, combinations, nor doses are specified in the protocol.

====Chemotherapy====
*[[Niraparib (Zejula)]] 300 mg PO once per day

'''Continued indefinitely'''

===References===
# '''NOVA:''' Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1611310 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27717299 PubMed]

==Olaparib monotherapy {{#subobject:f4c078|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 300 twice per day {{#subobject:81de0d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30469-2/fulltext Pujade-Lauraine et al. 2017 (SOLO2)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_2|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Patients had platinum-sensitive relapsed disease and BRCA1/2 mutations.''
====Chemotherapy====
*[[Olaparib (Lynparza)]] 300 mg PO twice per day

'''Continued indefinitely'''

===Variant #2, 400 twice per day {{#subobject:68e02d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1105535 Ledermann et al. 2012 (Study 19)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Placebo_2|Placebo]]
| style="background-color:#d9ef8b" |Might have superior OS (*)
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/abstract Oza et al. 2014 (D0810C00041)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
''Reported efficacy for Study 19 is based on the 2018 update; although p=0.02, the authors state that "the predefined threshold for statistical significance was not met."''
====Preceding treatment====
*D0810C00041: [[#Carboplatin.2C_Olaparib.2C_Paclitaxel.2C|Carboplatin, Olaparib, Paclitaxel]]
====Chemotherapy====
*[[Olaparib (Lynparza)]] 400 mg PO twice per day

'''Continued indefinitely'''

===References===
# '''Study 19:''' Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. [https://www.nejm.org/doi/full/10.1056/NEJMoa1105535 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22452356 PubMed]
## '''Update:''' Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. Epub 2016 Sep 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30376-X/abstract link to orignal article] [https://www.ncbi.nlm.nih.gov/pubmed/27617661 PubMed]
## '''Update:''' Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 Oct;119(9):1075-1085. Epub 2018 Oct 24. [https://www.nature.com/articles/s41416-018-0271-y link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30353045 PubMed]
# '''D0810C00041:''' Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25481791 PubMed]
<!-- # '''Abstract:''' Kathleen N. Moore, Paul DiSilvestro, Elizabeth S. Lowe, Sally Garnett, Eric Pujade-Lauraine. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). 2014 ASCO Annual Meeting abstract TPS5616. [http://meetinglibrary.asco.org/content/131636-144 link to abstract] -->
# '''SOLO2:''' Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30469-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28754483 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1105535 Ledermann et al. 2012 (Study 19)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Olaparib_monotherapy_3|Olaparib]]
| style="background-color:#fee08b" |Might have inferior OS (*)
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1611310 Mirza et al. 2016 (NOVA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Niraparib_monotherapy|Niraparib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30469-2/fulltext Pujade-Lauraine et al. 2017 (SOLO2)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Olaparib_monotherapy_3|Olaparib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32440-6/fulltext Coleman et al. 2017 (ARIEL3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rucaparib_monotherapy_2|Rucaparib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''No further active antineoplastic treatment. Reported efficacy for Study 19 is based on the 2018 update; although p=0.02, the authors state that "the predefined threshold for statistical significance was not met."''
====Preceding treatment====
*Platinum-based chemotherapy

===References===
# '''Study 19:''' Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. [https://www.nejm.org/doi/full/10.1056/NEJMoa1105535 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22452356 PubMed]
## '''Update:''' Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. Epub 2016 Sep 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30376-X/abstract link to orignal article] [https://www.ncbi.nlm.nih.gov/pubmed/27617661 PubMed]
## '''Update:''' Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 Oct;119(9):1075-1085. Epub 2018 Oct 24. [https://www.nature.com/articles/s41416-018-0271-y link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30353045 PubMed]
# '''NOVA:''' Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1611310 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27717299 PubMed]
# '''SOLO2:''' Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30469-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28754483 PubMed]
# '''ARIEL3:''' Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32440-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901715/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28916367 PubMed]

==Rucaparib monotherapy {{#subobject:218ca1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5c47ff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32440-6/fulltext Coleman et al. 2017 (ARIEL3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_2|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*Platinum-containing chemotherapy
====Chemotherapy====
*[[Rucaparib (Rubraca)]] 600 mg PO twice per day

'''28-day cycles'''

===References===
# '''ARIEL3:''' Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12.  [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32440-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901715/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28916367 PubMed]

=Relapsed or recurrent disease, platinum-resistant=
==Bevacizumab monotherapy {{#subobject:c0034f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:01c4a8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.11.5345 Burger et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.12.0782 Cannistra et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Nov 20;25(33):5165-71. Erratum in: J Clin Oncol. 2014 Nov 10;32(32):3686. [http://ascopubs.org/doi/full/10.1200/JCO.2007.11.5345 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18024863 PubMed]
# Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20;25(33):5180-6. Erratum in: J Clin Oncol. 2008 Apr 1;26(10):1773. [http://ascopubs.org/doi/full/10.1200/JCO.2007.12.0782 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18024865 PubMed]

==Docetaxel monotherapy {{#subobject:dc6ade|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e6d351|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(02)00091-4/abstract Rose et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO twice per day starting 24 hours before docetaxel, and continuing for 48 hours after docetaxel
*[[Diphenhydramine (Benadryl)]] 50 mg IV immediately prior to paclitaxel
*[[:Category:Emesis prevention|Antiemetics]] as needed

'''21-day cycles'''

===References===
# Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Feb;88(2):130-5. [http://www.gynecologiconcology-online.net/article/S0090-8258(02)00091-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12586591 PubMed]

==Doxorubicin pegylated liposomal monotherapy {{#subobject:cd6479|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 40 mg/m<sup>2</sup> {{#subobject:3cc773|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/6/890.long Ferrandina et al. 2008 (MITO-3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Gemcitabine_monotherapy|Gemcitabine]]
|style="background-color:#fee08b"|Might have inferior ORR
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Doxorubicin_pegylated_liposomal_.26_Bevacizumab|Pegylated liposomal doxorubicin & Bevacizumab]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.nature.com/bjc/journal/v116/n4/full/bjc2016435a.html Lindemann et al. 2017 (Ovaresist)]
|style="background-color:#1a9851"|Phase III (C)
|Tamoxifen
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note: '''Ovaresist''' met its primary endpoint of superior HrQOL for the experimental (tamoxifen) arm but had inferior PFS (secondary endpoint) for the experimental arm, and this is the efficacy reported here.''
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> IV over 60 minutes once on day 1

====Supportive medications====
*[[Methylprednisolone (Solumedrol)]] 20 mg IV once 30 minutes prior to chemotherapy

'''28-day cycles'''

===Variant #2, 50 mg/m<sup>2</sup> {{#subobject:8dcbc1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/19/14/3312.long Gordon et al. 2001 (Doxil Study 30-49)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Topotecan_monotherapy|Topotecan]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|[http://jco.ascopubs.org/content/25/19/2811.long Mutch et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gemcitabine_monotherapy|Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(09)00346-3/fulltext Vergote et al. 2009 (ASSIST-1)]
|style="background-color:#1a9851"|Phase III (C)
|Canfosfamide
|style="background-color:#1a9850"|Superior OS
|-
|[https://journals.lww.com/ijgc/Fulltext/2010/07000/Randomized_Phase_III_Study_of_Canfosfamide_in.13.aspx Vergote et al. 2010 (ASSIST-5)]
|style="background-color:#1a9851"|Phase III (C)
|Canfosfamide & PLD
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.25.4037 Monk et al. 2010 (OVA-301)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Doxorubicin_pegylated_liposomal_.26_Trabectedin|PLD & Trabectedin]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.38.8082 Colombo et al. 2012]
|style="background-color:#1a9851"|Phase III (C)
|Patupilone
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext Marth et al. 2016 (TRINOVA-2)]
|style="background-color:#1a9851"|Phase III (C)
|PLD & Trebananib
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''28-day cycles'''

===References===
# '''Doxil Study 30-49:''' Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22. [http://jco.ascopubs.org/content/19/14/3312.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11454878 PubMed]
## '''Update:''' Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 Oct;95(1):1-8. [http://www.gynecologiconcology-online.net/article/S0090-8258(04)00523-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15385103 PubMed]
<!-- Presented in part at the 29th European Congress on Clinical Oncology, October 30-November 3, 2005, Paris, France; and at the 37th Annual Meeting of the Society of Gynecologic Oncologists, March 22-26, 2006, Palm Springs, CA. -->
# Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007 Jul 1;25(19):2811-8. [http://jco.ascopubs.org/content/25/19/2811.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17602086 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''MITO-3:''' Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):890-6. [http://jco.ascopubs.org/content/26/6/890.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18281662 PubMed]
# '''ASSIST-1:''' Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S; ASSIST-1 Study Group. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer. 2009 Sep;45(13):2324-32. Epub 2009 Jun 8. [https://www.ejcancer.com/article/S0959-8049(09)00346-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19515553 PubMed]
<!-- # '''Abstract:''' I. Vergote, N. J. Finkler, J. B. Hall, O. Melnyk, R. P. Edwards, M. Jones, L. Meng, G. L. Brown, E. M. Rankin, J. J. Burke II, and P. G. Rose. Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC). Journal of Clinical Oncology 2009 27:15S, 5552-5552 [http://ascopubs.org/doi/abs/10.1200/jco.2009.27.15s.5552 link to abstract] -->
# '''ASSIST-5:''' Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2010 Jul;20(5):772-80. [https://journals.lww.com/ijgc/Fulltext/2010/07000/Randomized_Phase_III_Study_of_Canfosfamide_in.13.aspx link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20973267 PubMed]
# '''OVA-301:''' Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010 Jul 1;28(19):3107-14. Epub 2010 Jun 1. [http://ascopubs.org/doi/full/10.1200/JCO.2009.25.4037 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20516432 PubMed]
## '''Update:''' Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012 Oct;48(15):2361-8. Epub 2012 Apr 26. [https://www.sciencedirect.com/science/article/pii/S0959804912003218 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/22541893 PubMed]
# Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012 Nov 1;30(31):3841-7. Epub 2012 Sep 17. [http://ascopubs.org/doi/full/10.1200/JCO.2011.38.8082 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22987083 PubMed]
# '''AURELIA:''' Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. [http://jco.ascopubs.org/content/32/13/1302.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637997 PubMed]
## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed]
## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed]
# '''TRINOVA-2:''' Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017 Jan;70:111-121. Epub 2016 Dec 1. [https://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27914241 PubMed]
# Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. [https://www.nature.com/bjc/journal/v116/n4/full/bjc2016435a.html link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28118323 PubMed]

==Doxorubicin pegylated liposomal & Bevacizumab {{#subobject:c059ce|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:707619|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===References===
# '''AURELIA:''' Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. [http://jco.ascopubs.org/content/32/13/1302.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637997 PubMed]
## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed]
## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed]

==Doxorubicin pegylated liposomal & Gemcitabine {{#subobject:ea7f9f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7e0b4a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(05)00317-3/abstract Ferrandina et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV over 60 minutes once on day 1, given first
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8

====Supportive medications====
*[[Metoclopramide (Reglan)]] before chemotherapy

'''21-day cycles'''

===References===
# Ferrandina G, Paris I, Ludovisi M, D'Agostino G, Testa A, Lorusso D, Zanghi M, Pisconti S, Pezzella G, Adamo V, Breda E, Scambia G. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol. 2005 Aug;98(2):267-73. [http://www.gynecologiconcology-online.net/article/S0090-8258(05)00317-3/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15975643 PubMed]

==Doxorubicin pegylated liposomal & Trabectedin {{#subobject:edac44|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1e385c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.25.4037 Monk et al. 2010 (OVA-301)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV once on day 1
*[[Trabectedin (Yondelis)]] 1.1 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycles'''

===References===
# '''OVA-301:''' Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010 Jul 1;28(19):3107-14. Epub 2010 Jun 1. [http://ascopubs.org/doi/full/10.1200/JCO.2009.25.4037 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20516432 PubMed]
## '''Update:''' Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012 Oct;48(15):2361-8. Epub 2012 Apr 26. [https://www.sciencedirect.com/science/article/pii/S0959804912003218 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/22541893 PubMed]

==Etoposide monotherapy {{#subobject:a7d95b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:98f6b8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/16/2/405.long Rose et al. 1998]
|style="background-color:#91cf61"|Phase II
|ORR: 27%
|-
|}
====Chemotherapy====
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 21
**Dosage for patients with previous pelvic radiation: 30 mg/m<sup>2</sup> PO once per day on days 1 to 21; dose could be increased up to 50 mg/m<sup>2</sup> depending on toxicity

'''28-day cycles'''

===References===
# Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10. [http://jco.ascopubs.org/content/16/2/405.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9469322 PubMed]

==Gemcitabine monotherapy {{#subobject:4d5e38|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 2 weeks out of 3 {{#subobject:562314|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/19/2811.long Mutch et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/34/21/2516.full Kurzeder et al. 2016 (PENELOPE)]
|style="background-color:#1a9851"|Phase III (C)
|Gemcitabine & Pertuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 & 8

'''21-day cycles'''

===Variant #2, 3 weeks out of 4 {{#subobject:30324a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/6/890.long Ferrandina et al. 2008 (MITO-3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
|style="background-color:#d9ef8b"|Might have superior ORR
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===References===
<!-- Presented in part at the 29th European Congress on Clinical Oncology, October 30-November 3, 2005, Paris, France; and at the 37th Annual Meeting of the Society of Gynecologic Oncologists, March 22-26, 2006, Palm Springs, CA. -->
# Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007 Jul 1;25(19):2811-8. [http://jco.ascopubs.org/content/25/19/2811.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17602086 PubMed]
# '''MITO-3:''' Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):890-6. [http://jco.ascopubs.org/content/26/6/890.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18281662 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 29-June 2, 2015. -->
# '''PENELOPE:''' Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. [http://jco.ascopubs.org/content/34/21/2516.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27269942 PubMed]

==Olaparib monotherapy {{#subobject:6ab358|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5cec53|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960893-8/fulltext Audeh et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970214-5/fulltext Gelmon et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|[http://jco.ascopubs.org/content/33/3/244.long Kaufman et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
''Patients in '''Kaufman et al. 2014''' were resistant to prior platinum-containing therapy.''
====Chemotherapy====
*[[Olaparib (Lynparza)]] 400 mg PO twice per day

'''Continued indefinitely'''

===References===
# Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):245-51. Epub 2010 Jul 6. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960893-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20609468 PubMed]
# Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011 Sep;12(9):852-61. Epub 2011 Aug 19. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970214-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21862407 PubMed]
<!-- Presented at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013. -->
# Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [http://jco.ascopubs.org/content/33/3/244.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25366685 PubMed]

==Paclitaxel monotherapy {{#subobject:57d35e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 80 mg/m<sup>2</sup> weekly {{#subobject:3fd910|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(05)00976-5/abstract Markman et al. 2006]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Paclitaxel_.26_Bevacizumab|Paclitaxel & Bevacizumab]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70244-X/fulltext Monk et al. 2014 (TRINOVA-1)]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel & Trebananib
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70115-4/abstract Pignata et al. 2015 (MITO 11)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Paclitaxel_.26_Pazopanib|Paclitaxel & Pazopanib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[http://jco.ascopubs.org/content/34/21/2516.full Kurzeder et al. 2016 (PENELOPE)]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel & Pertuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nature.com/bjc/journal/v116/n4/full/bjc2016435a.html Lindemann et al. 2017 (Ovaresist)]
|style="background-color:#1a9851"|Phase III (C)
|Tamoxifen
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note: '''PENELOPE''' reports giving paclitaxel on days 1, 8, 15 of a 21-day cycle, which is identical to the schedule below. '''Ovaresist''' met its primary endpoint of superior HrQOL for the experimental (tamoxifen) arm but had inferior PFS (secondary endpoint) for the experimental arm, and this is the efficacy reported here.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Dexamethasone (Decadron)]] 10 mg IV or PO once 30 to 60 minutes prior to [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg IV once 30 to 60 minutes prior to [[Paclitaxel (Taxol)]]
*[[:Category:H2-receptor_antagonists|H2 blocker]] 30 to 60 minutes prior to [[Paclitaxel (Taxol)]]

'''28-day cycles'''

===Variant #2, 175 mg/m<sup>2</sup>, q3wk {{#subobject:3fd910|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.12.2654 Eisenhauer et al. 1994]
|style="background-color:#1a9851"|Phase III (E)
|Paclitaxel 135 mg/m<sup>2</sup>
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034015/ Gore et al. 1995]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.6.2183 ten Bokkel Huinink et al. 1997]
|style="background-color:#1a9851"|Phase III (E)
|[[#Topotecan_monotherapy|Topotecan]]
| style="background-color:#fee08b" |Might have inferior TTP (*)
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.20.5.1232 Cantù et al. 1999]
|style="background-color:#1a9851"|Phase III (E)
|CAP
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.10.082 Omura et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel 250 mg/m<sup>2</sup>
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409494/ Buda et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|Epirubicin & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: reported efficacy for ten Bokkel Huinink et al. 1997 is based on the 2004 update.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
**Omura et al. 2003 gave over 24 hours

'''21-day cycles'''

===Variant #3, with range {{#subobject:3fd210|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annals.org/aim/article-abstract/703308/taxol-unique-antineoplastic-agent-significant-activity-advanced-ovarian-epithelial-neoplasms McGuire et al. 1989]
| style="background-color:#91cf61" |Phase II
|-
|[https://academic.oup.com/jnci/article-abstract/86/1/18/884247 Kohn et al. 1994]
| style="background-color:#91cf61" |Phase II
|-
|}
''Of historic interest.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]]

===References===
# McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273-9. [http://annals.org/aim/article-abstract/703308/taxol-unique-antineoplastic-agent-significant-activity-advanced-ovarian-epithelial-neoplasms link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2569287 PubMed]
# Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994 Dec;12(12):2654-66. [http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.12.2654 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7989941 PubMed]
# Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, Cunnion RE, Reed E. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994 Jan 5;86(1):18-24. [https://academic.oup.com/jnci/article-abstract/86/1/18/884247 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7505830 PubMed]
# Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer. 1995 Oct;72(4):1016-9. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034015/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/7547214 PubMed]
# ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun;15(6):2183-93. [http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.6.2183 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9196130 PubMed]
## '''Update:''' ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004 Jan;15(1):100-3. [https://academic.oup.com/annonc/article/15/1/100/143220 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14679127 PubMed]
# Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002 Mar 1;20(5):1232-7. [http://ascopubs.org/doi/full/10.1200/JCO.2002.20.5.1232 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11870165 PubMed]
# Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003 Aug 1;21(15):2843-8. Epub 2003 Jun 13. [http://ascopubs.org/doi/full/10.1200/JCO.2003.10.082 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12807937 PubMed]
# Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004 Jun 1;90(11):2112-7. [https://www.nature.com/articles/6601787 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409494/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15150623 PubMed]
# Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S; Gynecologic Oncology Group. Phase II trial of weekly paclitaxel (80 mg/m<sup>2</sup>) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jun;101(3):436-40. Epub 2005 Dec 2. [http://www.gynecologiconcology-online.net/article/S0090-8258(05)00976-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16325893 PubMed]
# '''AURELIA:''' Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. [http://jco.ascopubs.org/content/32/13/1302.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637997 PubMed]
## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed]
## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed]
# '''TRINOVA-1:''' Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul;15(8):799-808. Epub 2014 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70244-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24950985 PubMed]
## '''Update:''' Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct;143(1):27-34. Epub 2016 Aug 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)30983-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27546885 PubMed]
# '''MITO 11:''' Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. Epub 2015 Apr 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70115-4/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25882986 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 29-June 2, 2015. -->
# '''PENELOPE:''' Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. [http://jco.ascopubs.org/content/34/21/2516.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27269942 PubMed]
# '''Ovaresist:''' Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. [https://www.nature.com/bjc/journal/v116/n4/full/bjc2016435a.html link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28118323 PubMed]

==Paclitaxel & Bevacizumab {{#subobject:cb482a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:38effd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Paclitaxel_monotherapy_2|Paclitaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===References===
# '''AURELIA:''' Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. [http://jco.ascopubs.org/content/32/13/1302.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637997 PubMed]
## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed]
## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed]

==Paclitaxel & Pazopanib {{#subobject:e5d0ca|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:af50ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70115-4/abstract Pignata et al. 2015 (MITO 11)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Paclitaxel_monotherapy_2|Paclitaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week
*[[Pazopanib (Votrient)]] 800 mg PO once per day

'''Continued indefinitely'''

===References===
# Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. Epub 2015 Apr 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70115-4/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25882986 PubMed]

==Pazopanib monotherapy {{#subobject:86404d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ce993f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(10)00425-7/abstract Friedlander et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pazopanib (Votrient)]] 800 mg PO once per day

'''Continued indefinitely'''

===References===
# Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010 Oct;119(1):32-7. Epub 2010 Jun 27. [http://www.gynecologiconcology-online.net/article/S0090-8258(10)00425-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20584542 PubMed]

==Pemetrexed monotherapy {{#subobject:5baa02|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:4e68e8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690393/ Miller et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 900 mg/m<sup>2</sup> IV over 10 minutes once on day 1
**Dosage for patients with previous radiation therapy: 700 mg/m<sup>2</sup> IV over 10 minutes once on day 1

====Supportive medications====
*Folic acid 350 to 600 mcg PO once per day, starting 7 days before pemetrexed, to continue throughout therapy
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once 7 days before pemetrexed, then 1000 mcg IM once every 9 weeks
*[[Dexamethasone (Decadron)]] 4 mg PO twice per day the day before, the day of, and day after pemetrexed
*No NSAIDs (nonsteroidal anti-inflammatory drugs) for 2 days before or after pemetrexed 

'''21-day cycles'''

===References===
# Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 1;27(16):2686-91. Epub 2009 Mar 30. [http://jco.ascopubs.org/content/27/16/2686.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690393/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19332726 PubMed]

==Topotecan monotherapy {{#subobject:7dbd5a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 4 mg/m<sup>2</sup>, 3 weeks out of 4 {{#subobject:a8bc04|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/2/242.long Sehouli et al. 2011 (TOWER<sub>ov</sub>)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|5-day topotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Topotecan_.26_Bevacizumab|Bevacizumab & Topotecan]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Note: TOWER should not be confused with the trial by the same name in B-ALL.''
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 4 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycle for up to 12 months (TOWER) or indefinitely (AURELIA)'''

===Variant #2, 6.25 mg/m<sup>2</sup>, split dosing, q3wk {{#subobject:a6c302|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.15.1258 Sehouli et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|1. Etoposide & Topotecan<br> 2. Gemcitabine & Topotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(09)00273-X/fulltext Meier et al. 2009 (AGO-OVAR 2.3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Treosulfan_monotherapy|Treosulfan]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://jco.ascopubs.org/content/29/2/242.long Sehouli et al. 2011 (TOWER<sub>ov</sub>)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Weekly topotecan
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Topotecan_.26_Bevacizumab|Topotecan & Bevacizumab]]
|style="background-color:#d73027"|Inferior PFS
|-
|[http://jco.ascopubs.org/content/34/21/2516.full Kurzeder et al. 2016 (PENELOPE)]
|style="background-color:#1a9851"|Phase III (C)
|Topotecan & Pertuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this was the dosing used in third-line therapy in AGO-OVAR 2.3.TOWER should not be confused with the trial by the same name in B-ALL.''
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.25 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5

'''21-day cycle for up to 12 months (TOWER) or indefinitely (AGO-OVAR 2.3; AURELIA; PENELOPE)'''

===Variant #3, 7.5 mg/m<sup>2</sup>, split dosing, q3wk {{#subobject:2bf80a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/19/14/3312.long Gordon et al. 2001 (Doxil Study 30-49)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
|style="background-color:#fee08b"|Might have inferior PFS
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(09)00273-X/fulltext Meier et al. 2009 (AGO-OVAR 2.3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Treosulfan_monotherapy|Treosulfan]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''Note: this was the dosing used in second-line therapy in AGO-OVAR 2.3.''
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.5 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5

'''21-day cycles'''

===References===
# '''Doxil Study 30-49:''' Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22. [http://jco.ascopubs.org/content/19/14/3312.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11454878 PubMed]
## '''Update:''' Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 Oct;95(1):1-8. [http://www.gynecologiconcology-online.net/article/S0090-8258(04)00523-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15385103 PubMed]
# Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008 Jul 1;26(19):3176-82. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.1258 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18591555 PubMed]
# '''AGO-OVAR 2.3:''' Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: a prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009 Aug;114(2):199-205. Epub 2009 May 14. [https://www.gynecologiconcology-online.net/article/S0090-8258(09)00273-X/fulltext link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/19446314 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL. -->
# '''TOWER:''' Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011 Jan 10;29(2):242-8. Epub 2010 Nov 29. [http://jco.ascopubs.org/content/29/2/242.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21115872 PubMed]
# '''AURELIA:''' Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. [http://jco.ascopubs.org/content/32/13/1302.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637997 PubMed]
## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed]
## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 29-June 2, 2015. -->
# '''PENELOPE:''' Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. [http://jco.ascopubs.org/content/34/21/2516.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27269942 PubMed]

==Topotecan & Bevacizumab {{#subobject:7994da|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, topotecan 3 weeks out of 4 {{#subobject:5a9474|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Topotecan_monotherapy|Topotecan]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 4 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #2, topotecan 6.25 mg/m<sup>2</sup>, split dosing, q3wk {{#subobject:352c9e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/13/1302.long Pujade-Lauraine et al. 2014 (AURELIA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Topotecan_monotherapy|Topotecan]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.25 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''AURELIA:''' Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. [http://jco.ascopubs.org/content/32/13/1302.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637997 PubMed]
## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed]
## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed]

==Trabectedin monotherapy {{#subobject:cfc3ed|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:33de2b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360276/ Krasner et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Trabectedin (Yondelis)]] 0.58 mg/m<sup>2</sup> IV over 3 hours once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17;97(12):1618-24. Epub 2007 Nov 13. [https://www.nature.com/articles/6604088 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360276/ link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18000504 PubMed]

==Treosulfan monotherapy {{#subobject:b8b3ed|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:22ce2b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(09)00273-X/fulltext Meier et al. 2009 (AGO-OVAR 2.3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Topotecan_monotherapy|Topotecan]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306340/ Sehouli et al. 2016]
|style="background-color:#1a9851"|Phase III (C)
|PO Treosulfan
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
====Chemotherapy====
*[[Treosulfan (Ovastat)]]

===References===
# '''AGO-OVAR 2.3:''' Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: a prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009 Aug;114(2):199-205. Epub 2009 May 14. [https://www.gynecologiconcology-online.net/article/S0090-8258(09)00273-X/fulltext link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/19446314 PubMed]
# Sehouli J, Tomè O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, Chekerov R, Muallem MZ, Lux MP, Trarbach T, Gitsch G. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). J Cancer Res Clin Oncol. 2017 Mar;143(3):541-550. Epub 2016 Nov 28. [https://link.springer.com/article/10.1007%2Fs00432-016-2307-0 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306340/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27896440 PubMed]

==Vinorelbine monotherapy {{#subobject:4884ac|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9e623e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(04)00707-3/abstract Rothenberg et al. 2004]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===References===
# Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol. 2004 Dec;95(3):506-12. [http://www.gynecologiconcology-online.net/article/S0090-8258(04)00707-3/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15581954 PubMed]

=Investigational agents=
''These are drugs under study with at least some promising results for this disease.''

*[[Selumetinib (AZD6244)]]

[[Category:Ovarian cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Gynecologic cancers]]
